South Dakota Investment Council Sells 11,000 Shares of Omnicell, Inc. (NASDAQ:OMCL)

South Dakota Investment Council trimmed its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 53.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,727 shares of the company’s stock after selling 11,000 shares during the period. South Dakota Investment Council’s holdings in Omnicell were worth $433,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of OMCL. Van ECK Associates Corp lifted its stake in shares of Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after purchasing an additional 315 shares during the last quarter. First Horizon Advisors Inc. raised its holdings in Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after buying an additional 355 shares during the period. KBC Group NV lifted its position in Omnicell by 60.8% in the fourth quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after buying an additional 778 shares during the last quarter. 1620 Investment Advisors Inc. boosted its stake in Omnicell by 230.1% during the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after buying an additional 1,542 shares during the period. Finally, CIBC Asset Management Inc bought a new position in Omnicell during the fourth quarter valued at $201,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Stock Performance

Shares of NASDAQ:OMCL opened at $39.83 on Tuesday. The firm’s 50 day simple moving average is $42.96 and its 200-day simple moving average is $43.89. The firm has a market cap of $1.84 billion, a PE ratio of 147.52, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. Omnicell, Inc. has a one year low of $25.12 and a one year high of $55.74. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, equities analysts predict that Omnicell, Inc. will post 1.09 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on OMCL. Craig Hallum raised their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. JPMorgan Chase & Co. raised their price objective on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. Barclays upped their target price on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Benchmark reissued a “buy” rating and set a $62.00 price target on shares of Omnicell in a research note on Tuesday, February 4th. Finally, Bank of America dropped their price objective on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $52.33.

Insider Buying and Selling at Omnicell

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the sale, the director now owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. This trade represents a 17.04 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 2.64% of the company’s stock.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.